The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The clinical efficacy of olaparib monotherapy or combination with ceralasertib (AZD6738) in relapsed small cell lung cancer.
 
Sehhoon Park
Stock and Other Ownership Interests - Lunit
 
Peter G. Mortimer
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Simon Smith
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Heejung (Rosa) Kim
No Relationships to Disclose
 
Hyun Ae Jung
No Relationships to Disclose
 
Jong-Mu Sun
No Relationships to Disclose
 
Jin Seok Ahn
Honoraria - Amgen; AstraZeneca; BC World Pharmaceutical; Bristol-Myers Squibb-Ono Pharmaceutical; Eisai; Janssen; Menarini; MSD; Mundipharma; Pfizer; Roche
Consulting or Advisory Role - Samsung Bioepis
 
Myung-Ju Ahn
Honoraria - AstraZeneca; Lilly; MSD; TAKEDA
Consulting or Advisory Role - Alpha pharmaceutical; AstraZeneca; Boehringer Ingelheim; Lilly; MSD; TAKEDA
 
Woong-Yang Park
No Relationships to Disclose
 
Se-Hoon Lee
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Roche
Research Funding - Merck
Travel, Accommodations, Expenses - Novartis
 
Keunchil Park
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; JNJ; Lilly; LOXO; Merck KGaA; MSD; Ono Pharmaceutical; Puma Biotechnology
Speakers' Bureau - Boehringer Ingelheim
Research Funding - AstraZeneca; MSD Oncology